This company is no longer active
Homology Medicines Balance Sheet Health
Financial Health criteria checks 4/6
Homology Medicines has a total shareholder equity of $73.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $84.6M and $11.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$82.65m |
| Equity | US$72.99m |
| Total liabilities | US$11.57m |
| Total assets | US$84.56m |
Recent financial health updates
Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely
Nov 16
Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation
Jan 28We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth
Sep 18Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans
Apr 17Recent updates
Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely
Nov 16Homology Medicines appoints new CEO, chairperson
Sep 06Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid
Jul 05Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation
Jan 28Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online
Oct 22We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth
Sep 18Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%
Aug 14Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts
May 22Homology Medicines (FIXX) Investor Presentation - Slideshow
May 05Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans
Apr 17Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?
Mar 13Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year
Feb 03Financial Position Analysis
Short Term Liabilities: FIXX's short term assets ($83.9M) exceed its short term liabilities ($11.6M).
Long Term Liabilities: FIXX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: FIXX is debt free.
Reducing Debt: FIXX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FIXX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: FIXX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.2% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/26 14:16 |
| End of Day Share Price | 2024/03/25 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Homology Medicines, Inc. is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Jason Zemansky | BofA Global Research |
| Madhu Kumar | B. Riley Securities, Inc. |